The use of novel therapies, specifically targeting type I IFN signalling, such as the monoclonal anti-IFNAR1 antibody anifrolumab [48], will help in discriminating the IFN-dependent and independent pathogenesis of COPA syndrome. Here, IFNAR1 is linked to autoimmune interstitial lung disease-arthritis syndrome.